



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/574,631	
			Filing Date	January 31, 2007	
			First Named Inventor	OSMAN N. OZES	
			Art Unit	1614	
			Examiner Name	Henley III, Raymond J.	
Sheet	1	of	5	Attorney Docket Number	30481/30010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)			
A	A1	US 2001/0036955	11-01-2001	Genentech, Inc.	
	A2	US 2002/0156023	10-24-2002	Tularik Inc.	
	A3	US 3,547,119	12-15-1970	Baxter Laboratories, Inc.	
	A4	US 3,760,984	09-25-1973	Alza Corporation	
	A5	US 3,839,346	10-01-1974	Affiliated Medical Research Inc.	
	A6	US 3,845,770	11-05-1974	Alza Corporation	
	A7	US 3,916,899	11-04-1975	Alza Corporation	
	A8	US 3,923,426	12-02-1975	Alza Corporation	
	A9	US 3,974,281	08-10-1976	Affiliated Medical Research, Inc.	
	A10	US 3,987,790	10-26-1976	Alza Corporation	
	A11	US 3,995,631	12-07-1976	Alza Corporation	
	A12	US 4,016,880	04-12-1977	Alza Corporation	
	A13	US 4,036,228	07-19-1977	Alza Corporation	
	A14	US 4,042,699	08-16-1977	Affiliated Medical Research, Inc.	
	A15	US 4,052,509	10-04-1977	Affiliated Medical Research, Inc.	
	A16	US 4,111,202	09-05-1978	Alza Corporation	
	A17	US 4,111,203	09-05-1978	Alza Corporation	
	A18	US 4,203,440	05-20-1980	Alza Corporation	
	A19	US 4,203,442	05-20-1980	Alza Corporation	
	A20	US 4,210,139	07-01-1980	Alza Corporation	
	A21	US 4,311,137	01-19-1982	Sherwood Medical Industries Inc.	
	A22	US 4,327,725	05-04-1982	Alza Corporation	
	A23	US 4,350,155	09-21-1982	Medtronic, Inc.	
	A24	US 4,360,019	11-23-1982	Andros Incorporated	
	A25	US 4,487,603	12-11-1984	Cordis Corporation	
	A26	US 4,531,937	07-30-1985	Pacesetter Systems, Inc.	
	A27	US 4,627,850	12-09-1986	Alza Corporation	
	A28	US 4,692,147	09-08-1987	Medtronic, Inc.	
	A29	US 4,695,623	09-22-1987	Amgen	
	A30	US 4,725,852	02-16-1988	Burlington Industries, Inc.	
	A31	US 4,741,900	05-03-1988	Cytogen Corporation	
	A32	US 4,755,173	07-05-1988	Pacesetter Infusion, Ltd.	
	A33	US 4,810,804	03-07-1989	Allergen, Inc.	
	A34	US 4,865,845	09-12-1989	Alza Corporation	
	A35	US 4,897,471	01-30-1990	Amgen	
	A36	US 5,057,318	10-15-1991	Alza Corporation	
	A37	US 5,059,423	10-22-1991	Alza Corporation	
	A38	US 5,112,614	05-12-1992	Alza Corporation	
	A39	US 5,137,727	08-11-1992	Alza Corporation	
	A40	US 5,200,534	04-06-1993	University of Florida	
	A42	US 5,229,529	07-20-1993	R-Tech Ueno Ltd.	
	A43	US 5,234,692	08-10-1993	Alza Corporation	
	A44	US 5,234,693	08-10-1993	Alza Corporation	
	A45	US 5,274,137	12-28-1993	Nicolaou, K.C. et al.	
	A46	US 5,279,949	01-18-1994	Board of Trustees operating Michigan State University	

Examiner Signature	<i>TR/Hjg</i>	Date Considered	12/6/07
-----------------------	---------------	--------------------	---------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/574,631
				Filing Date	January 31, 2007
				First Named Inventor	OSMAN N. OZES
				Art Unit	1614
				Examiner Name	Henley III, Raymond J.
Sheet	2	of	5	Attorney Docket Number	30481/30010

A47	US 5,283,253	02-01-1994	Florida State University	
A48	US 5,294,637	03-15-1994	Bristol-Myers Squibb Company	
A49	US 5,310,562	05-10-1994	Margolin, Solomon B.	
A50	US 5,382,657	01-17-1995	Hoffmann-La Roche Inc.	
A51	US 5,395,760	03-07-1995	Immunex Corporation	
A52	US 5,399,586	03-21-1995	Allergan, Inc.	
A53	US 5,415,869	05-16-1995	The Research Foundation of State University of New York	
A54	US 5,443,450	08-22-1995	Medtronic, Inc.	
A55	US 5,466,861	11-14-1995	SRI International; La Jolla Cancer Research Foundation	
A56	US 5,518,729	05-21-1996	Margolin, Solomon B.	
A57	US 5,605,690	02-25-1997	Immunex Corporation	
A58	US 5,643,207	07-01-1997	Medtronic, Inc.	
A59	US 5,643,575	07-01-1997	Enzon, Inc.	
A60	US 5,672,662	09-30-1997	Shearwater Polymers, Inc.	
A61	US 5,690,925	11-25-1997	Genentech, Inc.	
A62	US 5,716,632	02-10-1998	Margolin, Solomon B.	
A63	US 5,728,396	03-17-1998	Alza Corporation	
A64	US 5,770,378	06-23-1998	Ligand Pharmaceuticals, Inc.	
A65	US 5,770,382	06-23-1998	Ligand Pharmaceuticals, Inc.	
A66	US 5,770,383	06-23-1998	Ligand Pharmaceuticals, Inc.	
A67	US 5,780,676	07-14-1998	Ligand Pharmaceuticals Incorporated	
A68	US 5,814,019	09-29-1998	Fresenius AG	
A69	US 5,820,589	10-13-1998	Medtronic, Inc.	
A70	US 5,821,263	10-13-1998	Bristol-Myers Squibb Company	
A71	US 5,824,685	10-20-1998	The Johns Hopkins University School of Medicine; Allergan	
A72	US 5,824,701	10-20-1998	Enzon, Inc.	
A73	US 5,869,680	02-09-1999	Rhone-Poulenc Rorer, S.A.	
A74	US 5,951,974	09-14-1999	Enzon, Inc.	
A75	US 5,962,478	10-05-1999	Margolin, Solomon B.	
A76	US 5,976,109	11-02-1999	Medtronic, Inc.	
A77	US 5,981,709	11-09-1999	Enzon, Inc.	
A78	US 5,985,265	11-16-1999	Amgen Inc.	
A79	US 5,985,305	11-16-1999	Alza Corporation	
A80	US 6,017,328	01-25-2000	Magnolia Medical, LLC	
A81	US 6,046,305	04-04-2000	MacroMed, Inc.	
A82	US 6,090,822	07-18-2000	Margolin, Solomon B.	
A83	US 6,171,276	01-09-2001	Pharmacia & Upjohn AB	
A84	US 6,198,966	03-06-2001	Medtronic, Inc.	
A85	US 6,214,542	04-10-2001	The United States of America as represented by the Department of Health and Human Services	
A86	US 6,214,854	04-10-2001	SmithKline Beecham Corporation	
A87	US 6,241,704	06-05-2001	SIMS Deltec, Inc.	
A88	US 6,300,349	10-09-2001	Margolin, Solomon B.	
A89	US 6,464,687	10-15-2002	Ball Semiconductor, Inc.	
A90	US 6,475,180	11-05-2002	SIMS Deltec, Inc.	

Examiner Signature	<i>Raymond J. Henley III</i>	Date Considered	12/6/07
--------------------	------------------------------	-----------------	---------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/574,631
				Filing Date	January 31, 2007
				First Named Inventor	OSMAN N. OZES
				Art Unit	1614
				Examiner Name	Henley III, Raymond J.
Sheet	3	of	5	Attorney Docket Number	30481/30010

A91	US 6,489,325	12-03-2002	SmithKline Beecham Corporation
A92	US 6,492,395	12-10-2002	Mepha AG
A93	US 6,497,871	12-24-2002	Genentech, Inc.
A94	US 6,512,954	01-28-2003	Intermedics, Inc.
A95	US 6,541,447	04-01-2003	B & M Healthcare Technologies, Inc.
A96	US 6,548,520	04-15-2003	SmithKline Beecham Corporation
A97	US 6,569,871	05-27-2003	SmithKline Beecham Corporation
A98	US 6,579,856	06-17-2003	Mercola, Daniel
A99	US 6,680,335	01-20-2004	Sugen, Inc.
A100	US 6,943,161	09-13-2005	Pharmacoepia Drug Discovery, Inc.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code* -Number* -Kind Code* (if known)	MM-DD-YYYY			
B1	B1	EP 590,267	05-08-2002	Bristol-Myers Squibb Company		
	B2	WO 1990/04036	04-19-1990	Medical Research Council Agriculture and Food Research Council		
	B3	WO 1990/10077	09-07-1990	Celltech Limited		
	B4	WO 1992/02190	02-20-1992	Silverman, Harvey N.		
	B5	WO 1993/10076	05-27-1993	University of Mississippi		
	B6	WO 1993/23555	11-25-1993	The Penn State Research Foundation		
	B7	WO 1994/07876	04-14-1994	Rhone-Poulenc Rorer S.A		
	B8	WO 1994/07880	04-14-1994	Rhone-Poulenc Rorer S.A.		
	B9	WO 1994/07881	04-14-1994	Rhone-Poulenc Rorer S.A.		
	B10	WO 1994/07882	04-14-1994	Rhone-Poulenc Rorer S.A.		
	B11	WO 1997/03106	01-30-1997	Shearwater Polymers, Inc.		
	B12	WO 1997/25428	07-17-1997	Genentech, Inc.		
	B13	WO 1997/27840	08-07-1997	Alza Corporation		
	B14	WO 1998/13059	04-02-1998	Bristol-Myers Squibb Company		
	B15	WO 1998/22451	05-28-1998	Daiichi Pharmaceutical Co., Ltd.		
	B16	WO 1998/58927	12-30-1998	Baker Norton Pharmaceuticals, Inc.		
	B17	WO 1999/09021	02-25-1999	Florida State University		
	B18	WO 1999/14209	03-25-1999	Kabushiki Kaisha Yakult Honsha		
	B19	WO 1999/18113	04-15-1999	Bio Research Corporation of Yokohama; Ensui Sugar Refining Co., Ltd.; Kaken Pharmaceutical Co., Ltd.		
B20	WO 2001/36001	05-25-2001	Maxygen Holdings Ltd.			

Examiner Signature		Date Considered	12/6/07
--------------------	---	-----------------	---------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/574,631		
		Filing Date	January 31, 2007		
		First Named Inventor	OSMAN N. OZES		
		Art Unit	1614		
		Examiner Name	Henley III, Raymond J.		
Sheet	4	of	5	Attorney Docket Number	30481/30010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>[Signature]</i>	C1	AUERBACH et al., "Assays for Angiogenesis: A Review", Pharmac. Ther., 51:1-11, 1991.	
	C2	BAERT et al., "Tumor Necrosis Factor α Antibody (Infliximab) Therapy Profoundly Down-regulates the Inflammation in Crohn's Ileocolitis", Gastroenterology, 116:22-28, 1999.	
	C3	BRUNT, "Grading and Staging the Histopathological Lesions of Chronic Hepatitis: The Knodell Histology Activity Index and Beyond", Hepatology, 31:241-246, 2000.	
	C4	CHAMOW et al., "Modification of CD4 Immunoadhesin with Monomethoxypoly(ethylene glycol) Aldehyde via Reductive Alkylation", Bioconj. Chem., 5:133-140, 1994.	
	C5	ELLIOTT et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α ", Arthritis Rheum., 36:1681-1690, 1993.	
	C6	ELLIOTT et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis", Lancet, 344:1105-1110, 1994.	
	C7	FORRER et al., "Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 Kinase Activities", Biol. Chem., 379:1101-1111, 1998.	
	C8	FRIEDLER et al., "Development of a functional backbone cyclic mimetic of the HIV-1 Tat Arginine-rich Motif", J. Biol. Chem., 275:23783-23789, 2000.	
	C9	GRAY et al., "Expression of human immune interferon cDNA in <i>E. coli</i> and monkey cells", Nature, 295:503-508, 1982.	
	C10	ISHAK, "Histological grading and staging of chronic hepatitis", J. Hepatol, 22:696-699, 1995.	
	C11	KNODELL, "Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis", Hepatology, 1:431-435, 1981.	
	C12	LEE et al., "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis", Nature, 372:739-746, 1994.	
	C13	LI et al., "Angiostatis steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization", Invest. Ophthalmol. Vis. Sci., 32:2898-2905, 1991.	
	C14	MASCI et al., "New and modified interferon alfas: preclinical and clinical data", Curr. Oncol. Rep., 5:108-113, 2003.	
<i>[Signature]</i>	C15	MASSEROLI et al., "Design and validation of a new image analysis method for automatic quantification of interstitial fibrosis and glomerular morphometry", Lab. Invest., 78:511-522, 1998.	
Examiner Signature	<i>[Signature]</i>		Date Considered
			12/6/07

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/574,631
				Filing Date	January 31, 2007
				First Named Inventor	OSMAN N. OZES
				Art Unit	1614
				Examiner Name	Henley III, Raymond J.
Sheet	5	of	5	Attorney Docket Number	30481/30010

<input checked="" type="checkbox"/>	C16	METAVIR, "Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C", Hepatology, 20:15-20, 1994.	
<input checked="" type="checkbox"/>	C17	MILLER et al., "Vascular endothelial growth factor/vascular permeability factor is temporarily and spatially correlated with ocular angiogenesis in a primate model", Am. J. Pathol., 145:574-584, 1994.	
<input type="checkbox"/>	C18	MOHLER et al., "Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists", J. Immunol., 151:1548-1561, 1993.	
<input type="checkbox"/>	C19	NICOLAOU et al., "Calicheamicin O ¹ : A rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity", Angew Chem. Int. Ed. Engl., 33:183-186, 1994.	
<input type="checkbox"/>	C20	O'REILLY et al., "Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma", Cell, 79:315-328, 1994.	
<input type="checkbox"/>	C21	OSBORN et al., "Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon- α fusion protein in cynomolgus monkeys", J. Pharmacol. Exp. Therap., 303:540-548, 2002.	
<input type="checkbox"/>	C22	PARK et al., "Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct", Anticancer Res., 1:373-376, 1981.	
<input type="checkbox"/>	C23	PIASCIK, "New antibody approved for treatment of rheumatoid arthritis", J. Am. Pharm. Assoc., 43:327-328, 2003.	
<input type="checkbox"/>	C24	RINDERKNECHT et al., "Natural Human Interferon- γ ", J. Biol. Chem., 259:6790-6797, 1984.	
<input type="checkbox"/>	C25	RYU et al., "Idiopathic pulmonary fibrosis: current concepts", Mayo Clin. Proc., 73:1085-1101, 1998.	
<input type="checkbox"/>	C26	SCHEUER, "Classification of chronic viral hepatitis: a need for reassessment", J. Hepatol., 13:372-374, 1991.	
<input type="checkbox"/>	C27	SHEPPARD et al., "IL-28, IL-29 and their class II cytokine receptor IL-28R", Nature, 4:63-68, 2003.	
<input type="checkbox"/>	C28	SMITH et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins", Science, 248:1019-1023, 1990.	
<input type="checkbox"/>	C29	SUN et al., "Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidene]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases", J. Med. Chem., 42:5120-5130, 1999.	
<input type="checkbox"/>	C30	SUN et al., "Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Fik-1/KDR), FGF-R1, and PDGF-R β tyrosine kinases", J. Med. Chem., 43:2655-2663, 2000.	
<input type="checkbox"/>	C31	International Search Report for PCT/US2004/035390 mailed June 1, 2005.	
<input checked="" type="checkbox"/>	C32	Written Opinion of the International Searching Authority (US), mailed June 1, 2005 for PCT/US2004/035390.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/6/07
--------------------	---	-----------------	---------